Answer
The estimated steady-state half-life of ofatumumab is approximately 11 days following repeated 20 mg subcutaneous administration.
Sources for this answer
- Kesimpta 20 mg solution for injection in pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 9Document updated
Sources checked